Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ResApp Health (RAP) receives approval to modify its US-based SARS-CoV2 clinical study
  • The Institutional Review Board (IRB) approved modifications to COVID-Cough, ResApp’s COVID-19 clinical trial, to allow recruitment at in-person testing clinics
  • The study aims to secure data to train an algorithm to identify COVID-19 through cough sounds recorded on a smartphone, using a PCR pathology test as a reference standard
  • The COVID-Cough study will recruit up to 1500 subjects, with enrolment expected to complete mid-December 2021
  • ResApp Health was up 5.88 per cent, trading at 5.4 cents at 11:55 am AEDT

ResApp Health (RAP) has received approval to modify its US-based SARS-CoV2 clinical study.

The Institutional Review Board (IRB) approved modifications to COVID-Cough, ResApp’s COVID-19 clinical study, to allow recruitment at in-person testing clinics.

ResApp partnered with COVID Clinic, a network of testing sites in the US, to recruit 100 COVID-19 PCR-confirmed subjects at seven of its COVID-19 testing clinics in California.

PCR stands for polymerase chain reaction and is a test widely considered to be the most reliable way to determine whether a patient is COVID-19 positive.

The aim of the COVID-Cough pilot clinical study is to secure data to train an algorithm to identify COVID-19 through cough sounds recorded on a smartphone, using a PCR pathology test as a reference standard.

“Adding the option of recruiting patients at in-person COVID-19 testing clinics will substantially increase our recruitment rate and gives us a high level of confidence that we will complete recruitment by mid-December,” CEO and Managing Director, Dr Tony Keating said.

“With our study in India also recruiting exceptionally well, we are pleased to have a growing dataset of patients from multiple continents to perform the algorithm training and validation processes needed to build an instant smartphone-based screening test for COVID-19.”

The COVID-Cough study aims to recruit up to 1500 subjects altogether, with enrolment expected to complete in mid-December 2021.   

ResApp Health was up 5.88 per cent, trading at 5.4 cents at 11:55 am AEDT

RAP by the numbers
More From The Market Herald

" Indoor Skydiving (ASX:IDZ) officially changes name to xReality Group

Indoor Skydiving (IDZ) has officially changed its name to become xReality Group (XRG).
Wide Open Agriculture (ASX:WOA)

" Wide Open Agriculture (ASX:WOA) milks new Middle East distribution deal

Wide Open Agriculture (WOA) has penned a deal which will see its oat milk distributed across the Middle East.
icetana Limited, ICE - CEO, Matthew Macfarlane

" icetana Limited (ASX:ICE) signs Memorandum of Understanding with Threat Protect (ASX:TPS)

icetana Limited (ICE) has signed a memorandum of understanding with Threat Protect Australia (TPS).
Hyperion Metals (ASX:HYM) - CEO and MD, Anastasios (Taso) Arima

" Hyperion Metals (ASX:HYM) signs MOU with Chemours

Hyperion Metals (HYM) has entered into a non-binding memorandum of understanding (MOU) with The Chemours Company.